Podcasts about Neuroimaging

The diet world just picked another champion. This time it's intermittent fasting. The case for it is real, and so is the 38% dropout rate. This episode looks at what the data shows about both approaches, what the neuroscience says about where sustainable fat loss lives, and what question every protocol conversation is actually trying to ask. In This Episode: 1. The debate is a setup. Comparing protocols means staying inside the diet industry's frame. The tool isn't the problem. The relationship underneath it is. 2. Intermittent fasting works for one reason: total calorie reduction. Clinical trials confirm real results and a 38% dropout rate, higher than participants who cut calories with no time-based structure at all.3. The body reads a fasting window as a starvation signal. Cortisol rises. Ghrelin surges. When the eating window opens on a system flooded with hunger chemistry, control doesn't just get harder. Biology takes over. The body is running exactly the software it was designed to run. 4. Years of restriction damage the one skill mindful eating depends on. Interoception: the ability to feel hunger and fullness accurately. Every rule followed in place of an internal signal trains us further from our own bodies. Mindful eating's job is to recalibrate the compass that dieting broke. 5. The neuroscience is direct. Mindful eating doesn't manage cravings from above. It changes the wiring below. Neuroimaging shows it physically quiets the brain's reward pathway and strengthens the circuits where deliberate choice lives. The food noise gets quieter because the brain has changed its response to the signal. 6. Every conversation about fat loss eventually arrives at the same question. Not which protocol to follow. Who do you want to be in relationship with food? The thermostat is always an identity question. Mindful eating works at that level. Everything else reaches around it. Ready to go deeper? If this one landed, the next step isn't another protocol. It's a different target entirely. Escape the Willpower Trap is where we do this work, changing the relationship with food, not the meal schedule. The quiet mind is waiting. The door is open: https://news.weightlossmindset.co/subscribe

From IV therapies to PET scans and detox strategies, Dr. Josh shares what works in clinical settings to reverse dementia symptoms. #DementiaReversal #BrainDetox #NeuroImaging #FunctionalMedicine

By David Stephen who looks at Neuroimaging and prediction adiction in this article. There is a recent report in The New York Times, Minnesota Becomes First State to Ban Prediction Markets, stating that, "Under the law, a person who creates, operates or advertises a prediction market that allows users to place bets on future events could be charged with a felony punishable by up to five years in prison and a $10,000 fine. The law would not subject Minnesotans who bet on the sites to criminal penalties." "Millions of Americans bet billions of dollars each month on markets ranging from the price of oil to who will win the reality show "Survivor." The markets have come under heightened scrutiny as suspicious trades have come to light and fueled concerns about insider trading." "Hundreds of other unusual bets have also raised eyebrows. A New York Times analysis of Polymarket data showed hundreds of bets placed one day before the United States launched an attack on Iran, suggesting some bettors may have known the strike was coming. In April, Kalshi said it had discovered three examples of congressional candidates placing bets on their own races." Problem gambling research lab with conceptual neuroimaging? There could be many ways to regulate prediction markets. However, the likelihood that they would eradicate most of the risks that people are exposed to might be slight. There are already gaming regulation suggestions, for example, in Europe to ensure that people do not bet using credit. There are several others around time limits, fewer betting options, and so on. However, these can be regarded as technical. This means that there are two approaches to dealing with problem gambling: a technical side and a mind side. Most of the ways that digital addictions, like social media, video games and others were approached has been lopsided. While progress was made, they were never as effective in amplifying willpower and providing measures of risks before certain consequential decisions. This is the reason to have a major problem gambling research lab, with conceptual neuroimaging as the core path, for mind safety, against prediction markets addiction. Simply, how can there be a dynamic display of the human mind, for relays and destinations that can show the reach of addiction in the mind? So, like a flowchart, there can be boxes and arrows, labeled with possible destinations of mind. Then, some data points [timing, type of game, odds, and so forth] can be used to decided relays, helping to show parallels of what is happening in the mind. It will especially show the addiction destinations and how they feedback to the pleasure destination, as well as ignore the consequences and caution destinations. The purpose is to ensure mind safety, so that people are aware of what is happening in their minds. This would be comparable to showing [say] the corrosion of something, given the effect of another substance. The application is a flowchart with different shapes representing destinations in the mind and then different lines and arrows representing relays. It will be dynamic, such that it can take some data, either entered manually or automatically, and then display the relays of mind, in the instance. It will be developed using data visualization algorithms, fitting in a flowchart format. It may also be pre-trained with some existing gaming data, to ensure that it is possible to automate tens of possibilities in the mind. The application will be miniaturized for compliance with some gaming apps aside from its standalone iteration. Some prediction markets can have this lab, while some other sports betting or addiction companies may do as well. Just to see the mind, score and fasten prevention against risks and losses. This solution will ensure that there is enough fairness to avoid people saying they did not have a choice or could not stop themselves. The application will standalone, but can also be displayed on the side of some apps, as well as...

In this episode of the Society of Critical Care Medicine (SCCM) Podcast, Diane C. McLaughlin, DNP, AGACNP-BC, CCRN, FNCS, FCCM, is joined by Aarti Sarwal, MD, FAAN, FNCS, RPNI, FCCM, and Brian L. Erstad, PharmD, FCCP, FASHP, MCCM, to discuss the 2026 guidelines for neuromuscular blockade in adult patients with acute respiratory distress syndrome. The guidelines, “Society of Critical Care Medicine Guidelines for the Administration of Neuromuscular Blockade in Adults With Acute Respiratory Distress Syndrome,” were published in the March issue of Critical Care Medicine. Drs. Sarwal and Erstad discuss how the evidence in two key trials, ACURASYS and PETAL-ROSE, has helped shape the recommendations provided in the SCCM guidelines. Despite how influential these trials were in shaping the recommendations, only conditional recommendations were made due to low or very low quality of evidence. The lack of evidence proved to be a driving factor in including a call to action in the guidelines. Future research priorities largely revolve around precision medicine and finding more patient-specific interventions to improve patient outcomes. Aarti Sarwal, MD, FAAN, FNCS, RPNI, FCCM, is a professor of neurology and the division chair of neurocritical care at Virginia Commonwealth University (VCU) School of Medicine in Richmond, Virginia, USA. She is also an associate editor of Critical Care Medicine, secretary of the American Society of Neuroimaging, and director of VCU-Wake Forest neuro-ultrasound courses. Brian L. Erstad, PharmD, FCCP, FASHP, MCCM, is a tenured professor and interim dean at the University of Arizona R. Ken Coit College of Pharmacy in Tucson, Arizona, USA. He is also a center investigator for the Center for Health Outcomes, a member of the BIO5 Institute and Comprehensive Center for Pain & Addiction and Pharmacoeconomics Research Center, and a codirector for the Arizona Clinical and Translational Research Graduate Certificate Program. Resources referenced in this podcast: Society of Critical Care Medicine Guidelines for the Administration of Neuromuscular Blockade in Adults With Acute Respiratory Distress Syndrome Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome

Creatine and Microbiomes A new 2026 Cell Metabolism study explores a compelling and increasingly central idea in modern biology: the gut/brain/immune/metabolism axis is not just associative, it is mechanistic. Specifically, Dr. Lu and colleagues investigate how the gut microbiota can directly influence depressive behavior by reshaping systemic and neural metabolism. This is another in a long running list of papers describing the amazing work that bacterial commensal microbes do for us. In this case, our minds and moods. "Although peripheral-brain crosstalk regulates energy metabolism, its role in depression remains unclear. Here, we used metabolic profiling to reveal elevated fecal creatine alongside reduced plasma and cerebrospinal fluid creatine in both patients with depression and mouse depression models. Exogenous creatine produced antidepressant-like effects mediated by gut microbiota. Bifidobacterium pseudolongum was identified as a significantly reduced gut bacterial species in depression, correlating with impaired creatine absorption. Subsequent supplementation with Bifidobacterium enhanced the antidepressant effects of creatine. Mechanistically, B. pseudolongum-derived acetate promoted the creatine transporter (Slc6a8) expression in intestinal epithelial cells via histone acetylation. The Slc6a8 mediated the antidepressant-like effects of creatine. Neuronal creatine deficiency influenced energetic metabolism and neurophysiological function. In patients with depression taking antidepressants, co-administration of creatine and Bifidobacterium increased plasma creatine levels and reduced depression scores. These findings identify the Bifidobacterium-creatine combination as a promising antidepressant strategy and highlight the critical role of gut-brain energy metabolism in depression." "The brain, as an energy-intensive organ, relies on precise metabolic regulation to maintain synaptic plasticity, neurotransmitter synthesis, and stress response systems. Accumulating evidence implicates energy metabolism dysregulation as a hallmark of depression. Neuroimaging studies using positron emission tomography (PET) have identified marked glucose hypometabolism in the medial prefrontal cortex (mPFC) of patients with depression. Cerebral mitochondrial dysfunction and ATP imbalance have been mechanistically linked to depression progression. Notably, emerging studies emphasize the bidirectional interplay between peripheral metabolic signals and central energy regulation, which is fundamental to neural metabolism. Clinical observations such as fatigue, appetite dysregulation, and unexplained weight fluctuations in patients with depression further suggest systemic metabolic disturbances spanning peripheral organs and the CNS.." (Lu et. al. 2026) This is next-level medicine. Mental health can no longer be framed as a disorder of genetics, experience, or circumstance alone. This work opens a clearer window, showing how the microbiome participates as an active partner, shaping brain function through the metabolites it helps produce and deliver. Compounds like creatine are no longer just peripheral players. They become signals, fuel, structure, and information, bridging gut and brain, metabolism and behavior.... and more Enjoy, Dr. M

In this episode, Dr. Orlando Barsottini and Dr. Malco Rossi discuss the main imaging findings and clues for the the diagnosis of genetic and sporadic ataxias.

Novel MRI biomarkers, including cortical lesions, the central vein sign, and paramagnetic rim lesions, are highly specific for MS and can aid diagnosis in select clinical scenarios, particularly early in the disease course or in atypical presentations. When used with appropriate MRI sequences, these markers can improve diagnostic sensitivity while helping prevent misdiagnosis. In this episode, Casey Albin, MD, speaks with Jiwon Oh, MD, PhD, FRCPC, FAAN, author of the article "Diagnostic Neuroimaging Biomarkers for Multiple Sclerosis" in the Continuum® April 2026 Multiple Sclerosis and Related Disorders issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Oh is the medical director of the Barlo Multiple Sclerosis Program at St. Michael's Hospital and an associate professor at the University of Toronto in Toronto, Ontario, Canada. Additional Resources Read the article: Diagnostic Neuroimaging Biomarkers for Multiple Sclerosis Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Full episode transcript available here Dr Albin: Spend any time in a neurology conference, and you are certain to hear about the new central vein sign, which, as I learn, is not actually all that new. But have you heard about cortical lesions or these paramagnetic rim lesions? Because today I have the privilege of talking to Dr Jiwon Oh about her article, and we're going to unpack all these new biomarkers in MS. Dr Jones: This is Dr Lyell Jones, editor in chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Albin: Hello, this is Dr Casey Albin. Today I'm interviewing Dr Jiwon Oh about her article on diagnostic neuroimaging biomarkers for Multiple Sclerosis, which appears in the April 2026 Continuum issue on multiple sclerosis. Welcome to the podcast. Thank you so much for being here. I'd love to start by having you introduce yourself to our listeners.  Dr Oh: Thanks, Casey. Hi, everybody. My name is Jiwon Oh and I'm a neurologist, mainly an MS specialist at Saint Michael's Hospital at the University of Toronto, and I'm the medical director of our MS program. Dr Albin: And you have written a really fantastic article that dives deep into some of the nitty gritty about these new diagnostic biomarkers that we find on the MRI that we're getting for our patients with multiple sclerosis. And I think we are going to get into a lot of that nitty gritty. How do we look for them? How do they improve our diagnostic specificity? This is really come a long way in shaping the advances for multiple sclerosis. And I'd kind of like to just start with the big picture. Like why do we need these more specific biomarkers?  Dr Oh: This set of diagnostic criteria in MS, it's actually a huge change in the field, and particularly for people like me who are really interested in developing new MRI measures, we're really, really excited because it's actually the first time since MRI was officially incorporated into the MS Diagnostic criteria, which was way back in 2001. It's the first time that we've actually been able to get newer, more advanced imaging measures beyond just simply detecting, new T2 lesions in the MS diagnostic criteria. So, it's a big moment in the field, and many of us are really excited about it in terms of why we need some of these newer, more specific imaging measures. Well, you know, diagnostic criteria always evolve over time for any disease state, and MS is one that we've recognized over the years. By the time someone actually presents with typical clinical symptoms and has diagnosed, whatever has been happening from a patho-biological standpoint has been happening probably for almost 5 to 10 years before that individual actually presents. And so, because of this recognition in the field and the fact that we're recognizing how important it is to first diagnose MS and then treat MS earlier and earlier, because we know that early treatment helps prevent more clinical outcomes. Diagnostic criteria over time have become much more permissive, meaning that we're doing everything that we can to try to facilitate a diagnosis of MS when we know that someone biologically has MS. But the problem with making diagnostic criteria more permissive, and it's obviously a good thing because you want to capture as many people with MS as early on as possible. The problem with making it permissive is there is this terrible risk of misdiagnosis. As clinicians, we all think we never make mistakes. But it turns out when you actually do studies, you do. And even at MS specialty centers, when studies have been done, 10% to 20% of people with MS are misdiagnosed. So, this is exactly why we need in diagnostic criteria that really help to facilitate a diagnosis. We need things that help us prevent misdiagnosis as well. And these are these specific imaging measures that have now been incorporated into the diagnostic criteria in many settings that will help to facilitate a diagnosis. But the really big perk is if you use them, you can help to prevent misdiagnosis as well.  Dr Albin: Yeah, that really shone through in your article that this was such a big step in towards being more specific about who were diagnosing. Also capturing more people, right? Trying to get those people that we, we don't want to miss because of all the things you say, you know, that allows them to accumulate more disability, have worse outcomes. Early diagnosis is so important. But I really did take away from your article just how critical these are and sharping our diagnostic acumen. And so just to jump right in, and you describe these three new biomarkers, these cortical lesions the central vein sign and paramagnetic rim lesions. And so just to kick things off let's start with cortical lesions I sort of conceptualize multiple sclerosis a disease of white matter. So, what's going on here?  Dr Oh: Yes. MS classically has always been described as a white matter disease. But it turns out when you look at brain and spinal cord tissue, as well as when you use kind of better sequences to actually look for lesions in the gray matter, it actually turns out there's a ton of lesions in the gray matter as well. And in fact, what's interesting is that regardless of whether it's the cortex or the deep gray matter, it's lesions within these areas that seem to have the highest relevance for clinical disability in MS. So, all this to say, of course, MS is a lesion that does affect white matter, but it also affects gray matter a lot. And maybe pathology within the gray matter is even more relevant to clinical disability. So, this is why we're really interested in being able to develop methods using MRI to more accurately visualize the gray matter, particularly the cortex, as well as deep gray matter structures like the thalamus. I should add the caveat that cortical lesions were actually included in the 2017 diagnostic criteria revisions, but they were included together with juxtacortical lesions, which are a typical area that MS lesions form. And so, this imaging measure, despite the fact that it is relatively novel and we consider it advanced, it hasn't been used that much only because it's not that easy to detect lesions within the cortex. And reasons for this include that you usually need higher field magnet platforms. And so, the typical clinical MRI scanners that are available kind of widely, regardless of whether you're at an academic center or a community center, are 1.5 Tesla magnets. And cortical lesions are actually really difficult to detect on those typical scanners. But when you get to like, say, three Tesla or seven Tesla, they're a lot easier to detect. But obviously that's a big hindrance to widespread use. And then you actually need very specialized sequences to adequately visualize cortical lesions. And these are not sequences that are usually collected for clinical purposes. So, it kind of requires convincing your radiologists that you need this additional sequence. And then it actually takes a lot of time and training to be able to adequately, accurately detect cortical lesions. So, despite the fact that it's actually very useful when you do have the appropriate MRI sequences and scanners to detect cortical lesions, even though they were incorporated into the 2017 criteria outside of specialty centers, they're not actually widely used. But when you do have the appropriate sequences, cortical lesions are actually pretty specific for MS. So, very helpful for a diagnosis in certain settings. But there's all these practical limitations that have really limited its widespread use. Dr Albin: That is a beautiful summary. So, it sounds like once we kind of get up to speed in terms of like the protocols for this, having the magnet strength for this, this will be really a game changer in terms of increasing the specificity and also maybe finding things that impact patient's clinical presentation and therefore quite meaningful. But it sounds like for most of us, this is probably not something that they're going to be adopting right away. Is that a fair assessment?  Dr Oh: Yes. And you know, they were included in the last diagnostic criteria revisions. And it really hasn't changed things very much, only because of these difficulties with, you know, requiring higher field magnet strengths and these specialized sequences and then needing training to kind of figure out how you can adequately detect cortical lesions. Dr Albin: Totally. So, the other thing we've heard a lot about, and I have to say, I was in the AAN fall conference not too long ago, and this came up quite a bit, was the central vein sign and the fascination with that, because it tells us a lot about the MS pathophysiology and again, increasing that specificity. And it seems like maybe this is one that we can more easily adopt in clinical practice. So, tell our listeners about what that is, how they detect it. How many do you need to find?  Dr Oh: Sure. And so, this is one of the imaging measures I'm really excited about. So, the central vein sign heard about it recently. And probably in the last ten years particularly in the MS field we're talking about it all the time. But just wanted to emphasize that the central vein sign is not something that is new. Even back in the 1800s, when Charcot described MS lesions in these ancient textbooks, he actually very clearly described that MS lesions form around the central vein. And that makes sense, because we know that these waves of peripherally mediated inflammation somehow get through the blood-brain barrier and cause this cascade of events leading to inflammation in the brain and spinal cord, which is what MS is. But we know that B cells in T cells require veins to get into the central nervous system. And so, it's no surprise, really, that MS lesions form around veins. And so, this is something that's been known pathologically. But the reason we're so excited about it now is because we actually have good enough iron-sensitive MRI sequences that allow us to see a central vein when it is present within a white matter lesion. As a neurologist, we know that there's probably hundreds and hundreds of different things that can cause white matter lesions in the brain. But when you use an appropriate iron-sensitive sequence and you see that many of them, if not most of them, actually have visible central veins, that tells you that this person very likely has MS. And so that's why we're so excited about it, because there have been many studies done in the last ten years. In fact, so much evidence generated in the last ten years that there have been I think it's now four systematic reviews and meta analyzes. Looking at the diagnostic properties of the central vein sign. And, you know, it turns out that when you look at people with MS, most of them have a pretty high proportion of white matter lesions that have visible central veins. And there's a lot of questions about, you know, how to best use the central vein sign. But when 40% or more of the white matter lesions that you see have visible central veins, then the likelihood of a diagnosis of MS is very high. So, this is why we're so excited about it in the MS field because it's a really useful diagnostic tool. You know, again when you have appropriate ion sensitive sequences, if you see someone with white matter lesions and you see that 40% or more of them have visible central veins, this tells you that this person very likely has MS.  Dr Albin: So, Dr Oh, I hear you say, you know, 40% of the lesions. Does that mean the neuro radiologist needs to look at every single lesion and then count how many have the central veins, or is there an easier way to do this? Dr Oh: Great question. Casey, there is definitely an easier way because our neuro radiologists would not be our friends anymore if we made them look at every white matter lesion and make sure that 40% of them had the central vein sign. So, because it's so time-consuming to use that 40% threshold, there's an easier criterion that has actually made it into the diagnostic criteria. And it's called Select Six. And what this means is when you have more than ten lesions, as long as you show that six of them have a visible central vein, you just have to count six with the central vein. Then you're done. So that means you're Select Six positive or central veins nine positive. However, if you have ten or fewer lesions, as long as you show that more than 50% of them show a visible central vein, then you are select six positive, and then you're done. So, as you can see, it's a much simpler criterion to apply, and it seems to perform almost as well as that 40% threshold, which is why that is the criterion that's made it into the new diagnostic criteria.  Dr Albin: Perfect. I love that we definitely do not want to make enemies with our neuro radiology colleagues, but yet they do so much for us. So perfect. I'm glad that we can, make their jobs a little easier without losing any specificity there, or just losing a touch of specificity there. All right. If I am working with a, you know, in a center that maybe doesn't do this all the time, am I just getting a run of the mill SWI sequence? Do I need to ask my radiologist for a special sequence? Or is this just, you know, you can get it from the typical array of what our patients are getting.  Dr Oh: You know, SWI is a widely available commercial sequence that's iron-sensitive, the ones that are typically commercially available, they can detect central veins, but there actually are little tweaks that you can do to make it a little more optimal. With the recent diagnostic criteria publication, which was, led by Xavier Montalban and recently published in Lancet Neurology. There's actually a companion MRI paper that was led by Frederick Barkov and Danny Wright. And the reason I'm specifically citing those papers is in that companion MRI paper, there's a table that has kind of optimal sequence parameters that you can use even with a conventional SWI sequence, to try to best detect the central vein sign. And then there's a wide range of different iron-sensitive sequences, and SWI is one of them, but the one that seems to have emerged as most sensitive to detect the central vein sign is something called the 3D T2*-EPI sequence. But the bottom line is there's a whole bunch of different iron-sensitive sequences that you can use, little tweaks that you can do to make them optimal, to be able to visualize central veins when they're present within white matter lesions. Dr Albin: Incredible. So like partner with your neuro radiologist, there is a great sounds like a field guide almost to this. So, it makes it easy to pick up in your standard of care so that you can make sure that you are detecting them at the optimal level to see that more specific diagnostic biomarker.  Dr Oh: Yes. And you know, in contrast to what we were talking about with cortical lesions, you can actually detect central veins when you use these iron-sensitive sequences at any field magnet. So even at 1.5 Tesla, particularly when you use contrast, which is often given with the diagnostic scan anyway, you can very easily detect a central vein. So that's a huge benefit because it allows for widespread use. As long as you work with your radiologist to get the right iron-sensitive sequences in.  Dr Albin: Yeah, that's incredible. I mean, I think that it really will be practice-changing. And then the last one that I think was honestly new to me, I feel like I had heard a lot about the central vein sign, but the whole new to me term was this paramagnetic rim lesion. So, what does that tell us about the underlying biology of MS? And are there any other things that might also have this finding that we should sort of be aware of? And how specific is it?  Dr Oh: You know, the central vein sign is kind of the main, really new imaging measure that's made it into every part of the MS diagnostic criteria. And then together with that paramagnetic rim lesions or we call them PRL or pearls for short, they've made it as well, but in a much more limited way only because there's not as much evidence that has accumulated over time to support the diagnostic utility of pearls. But first of all, what are pearls? So, people in the MS field are really excited about pearls, because we know that they capture a subset of what we call chronic active lesions. So, MS lesions will form acutely and over time, some of them will become inactive. And then some of them are chronic active lesions, meaning that they have this rim of activated microglia around them. Over time, they continue to slowly expand. And it's almost like this slow burn. And the reason why we focus a lot on chronic active lesions is because we know that they're a driver of progressive disease biology and MS, meaning that in people who have progressive MS or who have pretty severe disability, global disability or cognitive disability, we know that they have a high burden of pearls. And so that's why there's so much excitement in MS about being able to image chronic active lesions. It's because we're always looking for an imaging measure that allows us to accurately predict progression or to, measure progression over time. So that's why there's so much excitement in MS about pearls. But as kind of an added bonus, it turns out pearls are also really specific for MS. And so, when you use the same iron-sensitive sequences, by the way, that's used to detect the central vein sign when you use appropriate iron‑sensitive sequence. And if you see that someone has a pearl, the likelihood of a diagnosis of MS is very high. The one exception to that is Susac syndrome, where pearls have been observed. But other than that, with many other white matter diseases like neuro rheumatology disease, NMOSD, MOGAD, you really don't see pearls. And so, this is why it's made it into the new diagnostic criteria. In contrast to the central vein sign, though, not everybody with MS has a pearl, so the sensitivity isn't as high. However, it's really, really specific in the range of, you know, 90 to 95%. So, this is why it's been added as, an imaging measure in certain settings. It can help facilitate a diagnosis. But the real utility, again, is when you use it, it helps you to prevent misdiagnosis.  Dr Albin: It's fantastic. And hearing you talk about that, this one stands out to me as a biomarker that not only helps increase our diagnostic specificity, but also may really inform if the patient has having progression despite the treatment they're on, that this could play a role in helping you say, look, there probably is something that we need to switch because we can still see this ongoing progression. Dr Oh: Yes. And especially in this new era of treatment in MS. I think, you know, MS as a field, we've been so fortunate to have so many treatments emerge over the years that mainly target relapsing disease. But we hopefully, in the next little while, in short order, I hope we'll have treatments that target these progressive disease biologies. And so, not only is it helpful as a diagnostic marker, but there's a lot of evidence accumulating, showing that it may have a lot of prognostic value and will also help guide treatment decisions, exactly as you said.  Dr Albin: It truly does sound like it's a great time to be an MS doctor there. So, so many new advances in the field. There is so much more that we can do for these patients in our limited time left. I'd love to ask you, what is it that you're most excited about now with the change in the biomarkers, the change in the treatment, what makes you really excited to be a doctor specializing in MS right now? Dr Oh: I feel like we're on the brink of a new era of treatment. I think, you know, in the last two decades, MS care has changed so dramatically. I remember, you know, way back when, as a medical student, when I did my first neurology elective, this was when the first treatments for MS were emerging. And the prognosis that we were talking to patients about at that time is like night and day compared to what we talk to them about now. But we're going to do even better in the next couple of years. And so, there's a number of new treatments that hopefully will be approved soon that, for the first time, have shown an effect in clinical trials where it seems to be decreasing progression that is independent of relapsing activity. And that's really the greatest unmet treatment need that we have. And it seems like we might have some therapies on the horizon that can actually target that aspect of progression. It's really exciting, and even more that we're going to be able to do for our patients to completely change the way, we look at and the way we treat MS in the years to come.  Dr Albin: Dr Oh, this has just been fantastic. To all of our listeners, I really want to point you to the article because obviously, as an imaging biomarker article, there are so many beautiful images. There are great examples. There are some fantastic cases that show how applying these new biomarkers can help get you to the right diagnosis. This is truly a tour de force of how imaging has really shifted the care that we provide patients with MS, and so please go and check it out. It is one that you do not want to miss. And again, today I've been interviewing Dr Jiwon Oh about her article on diagnostic neuroimaging biomarkers for multiple sclerosis, which appears in the April 2026 Continuum issue on multiple sclerosis. Thank you again, Dr Oh, this has just been such a delight.  Dr Oh: Thank you for having me on the show, Casey, and look forward to people reading the article. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Addressing this gap will require collecting widespread data on pregnancy, menopause and other life events women experience—and could bring us closer to the “holy grail” of linking brain and behavior.

In this Worldviews episode, Jim talks with Iain McGilchrist about consciousness, matter, and the nature of reality. They discuss consciousness as the basis of everything we know, matter as a phase of consciousness that provides resistance and persistence, pan-experientialism and the belief that everything in the cosmos experiences in some form, the whirlpool metaphor for individual consciousness within a broader field, emergent naturalism and nested levels of organization, the question of whether the universe is continuous or granular at the Planck scale, consciousness in animals including chimps and corvids, language as the principal difference between human and animal consciousness, John Vervaeke's distinction between propositional and participatory knowing, the divided brain and how the left and right hemispheres attend to the world differently, the left hemisphere's focus on decontextualized abstractions versus the right hemisphere's grasp of interconnected wholes, how the left hemisphere deals with representations while the right hemisphere experiences presences, living in a world dominated by the relatively stupid left hemisphere, the relationship between consciousness and reality as an encounter rather than naive realism or idealism, relations coming before things, Lee Smolin's argument that time cannot be an illusion, assembly theory's challenge to the block universe, values as ontological primitives that cannot be derived from a valueless cosmos, the distinction between value and values, teleology as a lure rather than determinism using Waddington's creodes metaphor, the three elements of a fulfilled life (belonging to a coherent social group, belonging in nature, and belonging in the cosmos), the breakdown of collective sense making despite increased education levels, the decline in the caliber of political leaders, the distinction between information and wisdom, and much more. Episode Transcript The Master and His Emissary, by Iain McGilchrist The Matter with Things, by Iain McGilchrist JRS EP 154 - Iain McGilchrist on The Matter With Things JRS EP 155 Iain McGilchrist Part 2: The Matter With Things The Emergence of Everything, by Harold Morowitz Time Reborn, by Lee Smolin JRS EP 5 Lee Smolin - Quantum Foundations and Einstein's Unfinished Revolution Iain McGilchrist is a former Fellow of All Souls College, Oxford, an associate Fellow of Green Templeton College, Oxford, a Fellow of the Royal College of Psychiatrists, a Fellow of the Royal Society of Arts, a Consultant Emeritus of the Bethlem and Maudsley Hospital, London, a former research Fellow in Neuroimaging at Johns Hopkins University Medical School, Baltimore, and a former Fellow of the Institute of Advanced Studies in Stellenbosch. He now lives on the Isle of Skye, off the coast of North West Scotland, where he continues to write, and lectures worldwide. He is committed to the idea that the mind and brain can be understood only by seeing them in the broadest possible context, that of the whole of our physical and spiritual existence, and of the wider human culture in which they arise – the culture which helps to mould, and in turn is moulded by, our minds and brains.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KNB865. CME/AAPA/IPCE credit will be available until February 22, 2027.Alzheimer's Disease Case Conference: Building Confidence in Visual Interpretation and Quantitative Analysis of Neuroimaging In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KNB865. CME/AAPA/IPCE credit will be available until February 22, 2027.Alzheimer's Disease Case Conference: Building Confidence in Visual Interpretation and Quantitative Analysis of Neuroimaging In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KNB865. CME/AAPA/IPCE credit will be available until February 22, 2027.Alzheimer's Disease Case Conference: Building Confidence in Visual Interpretation and Quantitative Analysis of Neuroimaging In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KNB865. CME/AAPA/IPCE credit will be available until February 22, 2027.Alzheimer's Disease Case Conference: Building Confidence in Visual Interpretation and Quantitative Analysis of Neuroimaging In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Breakups are one of the most psychologically stressful life events we can experience.Neuroimaging studies show that when we go through heartbreak, the same pain centers in the brain that respond to physical pain are activated, particularly the anterior cingulate cortex.That's why it doesn't just feel emotional, it literally hurts.Now, for someone with Borderline Personality Disorder that pain can feel magnified.BPD is characterized by emotional intensity, fear of abandonment, unstable relationships, and a fragile sense of self. When someone with BPD goes through a breakup, it's not just the loss of a partner, it can feel like the loss of identity, safety, and purpose.Book a retreat call HEREVisit the retreat website HERE FREE Resources:Download my [FREE binge eating tracker tool] To access more of my courses use this:https://stan.store/mindfoodstephDo you have any questions? Ask Steph here. Social media:TikTokInstagramFacebookHelp lines Review the podcast on Apple By sharing, following, or rating the podcast, you help me reach more people so they can understand the importance of mental health. Hosted on Acast. See acast.com/privacy for more information.

Text Dr. Lenz any feedback or questions Navigating Chronic Pain and Pseudoscientific Treatments: A Deep DiveThe podcast episode features a conversation centered around the challenges and misconceptions in treating chronic conditions like fibromyalgia and ADHD. Topics covered include the shortcomings of mainstream medicine, supply issues of necessary medications, and the appeal of pseudoscientific treatments. Discussions extend to alternative therapies like EMDR for PTSD, their scientific validity, and potential psychological benefits. The episode critiques pseudoscientific grifts in wellness industries, emphasizes the importance of evidence-based medical approaches, and shares personal anecdotes to underline the significance of comprehensive, scientifically grounded care. The conversation concludes by advocating for skepticism over cynicism and the ethical duty of clinicians to empower patients with accurate information.00:00 Introduction and Patient Case Study00:05 Challenges with Fibromyalgia and ADHD00:31 Alternative Medicine and Root Causes01:43 Mainstream Medicine vs. Alternative Medicine03:08 Exploring EMDR Therapy03:54 The Purple Hat Metaphor05:15 Debate on EMDR's Effectiveness08:05 Neuroimaging and Mental Health Diagnosis11:54 Critique of Alternative Pain Models16:55 Red Flags in Evaluating Therapies19:08 Personal Story and Motivation22:14 Final Thoughts and Advocacy Click here for the YouTube channel Support the showWhen I started this podcast and YouTube Channel—and the book that came before it—I had my patients in mind. Office visits are short, but understanding complex, often misunderstood conditions like fibromyalgia takes time. That's why I created this space: to offer education, validation, and hope. If you've been told fibromyalgia “isn't real” or that it's “all in your head,” know this—I see you. I believe you. This podcast aims to affirm your experience and explain the science behind it. Whether you live with fibromyalgia, care for someone who does, or are a healthcare professional looking to better support patients, you'll find trusted, evidence-based insights here, drawn from my 29+ years as an MD. Please remember to talk with your doctor about your symptoms and care. This content doesn't replace per...

How should we think about diets that claim to optimise both human and planetary health? Can a single "reference diet" really balance the complex trade-offs between nutrition adequacy, chronic disease prevention, and environmental sustainability? These questions have gained renewed attention with the release of the 2025 update to the EAT-Lancet Planetary Health Diet. The original 2019 report proposed a mostly plant-based dietary pattern designed to improve population health while staying within planetary boundaries. But since then, new data have emerged—on nutrient requirements, disease risk, and environmental modelling—that complicate many of the original assumptions. What does the updated evidence actually say about the health impacts of eating in line with this framework? How have the environmental projections changed? And what do these evolving targets mean for individuals, policymakers, and researchers trying to translate broad sustainability goals into practical dietary guidance? These are some of the questions explored in this episode of Sigma Nutrition, which examines the 2025 EAT-Lancet update, its scientific foundations, and what it reveals about the intersection of nutrition, health, and planetary sustainability. Timestamps [01:46] Focus on the 2025 EAT-Lancet report [02:27] Overview of the Planetary Health Diet [03:13] Comparing 2019 and 2025 reports [03:40] Dietary recommendations and nutrient targets [04:14] Health and environmental impacts [09:12] Scoring methods and dietary patterns [27:00] Mortality and chronic disease outcomes [40:01] Type 2 diabetes [44:13] Neuroimaging and cognitive outcomes [49:48] Conclusions and practical implications [58:55] Key ideas segment (Premium-only) Links & Resources Go to episode page (with links to studies) Join the Sigma email newsletter for free Subscribe to Sigma Nutrition Premium Alan Flanagan's Alinea Nutrition Education Hub Enroll in the next cohort of our Applied Nutrition Literacy course Report: EAT-Lancet

Developments in neuroimaging have grown a lot over the years. Dr. Thilo van Eimeren discusses biomarker development, both in tau and alpha synuclein, current research, and his hope for future successes.

Warum rast unser Herz, bevor wir Angst haben? Warum spüren manche Menschen ihren Körper so genau – und andere fast gar nicht? In dieser Folge tauchen Leon und Atze in die Welt der Interozeption ein – dem verborgenen Sinn, mit dem wir unser Inneres wahrnehmen. Fühlt euch gut betreut Leon & Atze Instagram: https://www.instagram.com/leonwindscheid/ https://www.instagram.com/atzeschroeder_offiziell/ Mehr zu unseren Werbepartnern findet ihr hier: https://linktr.ee/betreutesfuehlen Tickets: Atze: https://www.atzeschroeder.de/#termine Leon: https://leonwindscheid.de/tour/ Empfehlungen Betreutes Fühlen – Folge zu Alexithymie (vom 12.03.2024) „Warum fühle ich nichts?“ In dieser Folge sprechen Leon und Atze darüber, warum manche Menschen Schwierigkeiten haben, ihre eigenen Gefühle wahrzunehmen und auszudrücken. Lisa Feldman Barrett – Wie Gefühle entstehen Ein faszinierendes Buch einer der bekanntesten Emotionsforscherinnen unserer Zeit. Barrett zeigt darin, dass Gefühle keine festen Programme sind, sondern vom Gehirn konstruiert werden. Quellen Desmedt, O., Luminet, O., Walentynowicz, M., & Corneille, O. (2023). The new measures of interoceptive accuracy: A systematic review and assessment. Neuroscience & Biobehavioral Reviews, 153, 105388. https://doi.org/10.1016/j.neubiorev.2023.105388 Ditzer, J., Woll, C. F. J., Burger, C., Ernst, A., Böhm, I., Garthus-Niegel, S., & Zietlow, A. L. (2025). A meta-analytic review of child maltreatment and interoception. Nature Mental Health, 1–17. https://doi.org/10.1038/s44220-025-00456-w Ekman, P. (1992). An argument for basic emotions. Cognition & Emotion, 6(3–4), 169–200. https://doi.org/10.1080/02699939208411068 Garfinkel, S. N., Gould van Praag, C. D., Engels, M., Watson, D., Silva, M., Evans, S. L., ... & Critchley, H. D. (2021). Interoceptive cardiac signals selectively enhance fear memories. Journal of Experimental Psychology: General, 150(6), 1165–1178. https://doi.org/10.1037/xge0000967 Garfinkel, S. N., Manassei, M. F., Hamilton-Fletcher, G., In den Bosch, Y., Critchley, H. D., & Engels, M. (2016). Interoceptive dimensions across cardiac and respiratory axes. Philosophical Transactions of the Royal Society B: Biological Sciences, 371(1708), 20160014. https://doi.org/10.1098/rstb.2016.0014 Garfinkel, S. N., Minati, L., Gray, M. A., Seth, A. K., Dolan, R. J., & Critchley, H. D. (2014). Fear from the heart: Sensitivity to fear stimuli depends on individual heartbeats. Journal of Neuroscience, 34(19), 6573–6582. https://doi.org/10.1523/JNEUROSCI.3507-13.2014 Gross, J. J. (2013). Emotion regulation: Taking stock and moving forward. Emotion, 13(3), 359–365. https://doi.org/10.1037/a0032135 Interoception: The mysterious inner sense driving your emotions. (2024, March 22). BBC Future. https://www.bbc.com/future/article/20240322-interoception-the-mysterious-inner-sense-driving-your-emotions Khalsa, S. S., Adolphs, R., Cameron, O. G., Critchley, H. D., Davenport, P. W., Feinstein, J. S., ... & Zucker, N. (2018). Interoception and mental health: A roadmap. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 3(6), 501–513. https://doi.org/10.1016/j.bpsc.2017.12.004 Murphy, J., Brewer, R., Plans, D., Khalsa, S. S., Catmur, C., & Bird, G. (2020). Testing the independence of self-reported interoceptive accuracy and attention. Quarterly Journal of Experimental Psychology, 73(1), 115–133. https://doi.org/10.1177/1747021819879826 Nord, C. L., Dalmaijer, E. S., Armstrong, T., Baker, K., & Dalgleish, T. (2021). A causal role for gastric rhythm in human disgust avoidance. Current Biology, 31(3), 629–634. https://doi.org/10.1016/j.cub.2020.10.087 Open Science Collaboration. (2015). Estimating the reproducibility of psychological science. Science, 349(6251), aac4716. https://doi.org/10.1126/science.aac4716 Redaktion: Julia Ditzer Produktion: Murmel Productions

What would it take to actually read someone's mind? Neil deGrasse Tyson and co-hosts Chuck Nice and Gary O'Reilly explore the science and ethics of decoding thoughts with Jean-Rémi King, a neuroscience researcher at Meta's Paris lab. NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free here: https://startalkmedia.com/show/mindreading-with-jean-remi-king/Thanks to our Patrons Eeshan Londhe, John Strack, Emmanuel Michaca, todd hauser, Justin Belcher, Gabriel Cuadros Caceres, Swaglass, Jon B, John Chase, systemcall, Jim Togyer, Darren Littlefair, Tim Rosener, Duygu Guler, shoulderutube, Kyle Telfer, Carol Cherich, Eduardo Lobato, Aladin, jlayton21, melissa prien, Ben, PuerFugax, LadyGemini, Holly Williams, Dr. Spin, Brent McAlister, Jonathan Hughes, Robert Hartman, James Tulip, Sleepy Blulys, Megan Childs, Esteban Pérez, Rodger Gamblin, Reka Royal, Nicholas Mckenzie, Damon Friedman, Joshua Hemphill, Nadia, Gregory Meyer, Jonathan Bassignani, Kellyn Gerenstein, Jahangiri, Halimah, Tomaz Lovsin, Michael Tombari, Andrei Mistretu, FelicitousFeild, ayadal, nelly, and Josh Christensen for supporting us this week. Subscribe to SiriusXM Podcasts+ to listen to new episodes of StarTalk Radio ad-free and a whole week early.Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus.

The growing spectrum of neurotoxicities related to targeted cancer therapies can present a challenge for radiologists. In this AJR Conversation, Neuroradiology Imaging Senior Editor Carlos Zamora, MD, PhD, speaks with Alvand Hasankhani, MD, about his team's recently published article addressing the critical role of neuroimaging in detecting and differentiating neurotoxicity syndromes associated with common and emerging cancer therapies.

Analyses that include low-quality MRI data underestimate cortical thickness and overestimate cortical surface area, according to new findings from the Adolescent Brain Cognitive Development (ABCD) Study.

The Smart 7 is an award winning daily podcast, in association with METRO that gives you everything you need to know in 7 minutes, at 7am, 7 days a week...With over 18 million downloads and consistently charting, including as No. 1 News Podcast on Spotify, we're a trusted source for people every day and the Sunday 7 won a Gold Award as “Best Conversation Starter” in the International Signal Podcast Awards If you're enjoying it, please follow, share, or even post a review, it all helps...Today's episode includes the following guests:Guests Yuji Iwasawa - The President on the International Court of Justice, The HagueRalph Regenvanu - Climate Minister for the Pacific Island State of Vanuatu Antonio Guterres - UN Secretary General Will Guyatt - The Smart 7's Tech Guru Tilly Lockey - Influencer, Disability Advocate and Bionic Woman Michael Shanks MP - UK Energy Minister Paul DeGedler - Shark Conservation Activist and host of “How to Survive a Shark Attack”Kinga Philipps - Travel journalist and host of “Dancing with the Sharks”Jessica Toale MP - Member of Cross Party Lobby Group for DES Victims Professor Karen Millinger - Expert in Neuro Imaging at the University of Nottingham Hans Skov - Board member of the organisation Stork Denmark Contact us over @TheSmart7pod or visit www.thesmart7.com or find out more at www.metro.co.uk Presented by Ciara Revins, written by Liam Thompson, researched by Lucie Lewis and produced by Daft Doris. Hosted on Acast. See acast.com/privacy for more information.

Welcome to the sixth season of the Dementia Researcher X ISTAART PIA Relay Podcast. This series features interviews with ISTAART PIA committee members talking about their research, the research landscape of their fields, and the work of the ISTAART Professional Interest Areas (PIA) they represent. As we build up to the Alzheimer's Association International Conference in Toronto, join us for daily episodes that showcase the remarkable work being done in various research fields. -- In this Relay Podcast episode, Dr Colin Groot interviews Dr Marta Del Campo, Head Fluid Biomarker Facility; Ramón y Cajal Research fellow at BarcelonaBeta Brain Research Center and chair of the ISTAART Biofluid Based Biomarkers PIA. Together, they talk about recent advances in fluid biomarkers in dementia research, and explore the growing role of plasma biomarkers, integration with clinical trials, challenges with reproducibility and diversity, and the promise of proteomics and AI. Marta also reflects on the work of ISTAART, their plans for AAIC, the value of publishing negative findings, and why ISTAART offers vital opportunities for early career researchers. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org -- Find more information on our guests, and a full transcript of this podcast on our website at: http://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Curious about the manifestation secrets that can turn your dreams into reality? In this episode of the Manifested podcast, Kathleen Cameron is joined once again by Dr. Steven Resnick, who dives deep into the powerful connection between personal manifestation stories and the subconscious mind. Dr. Resnick shares his fascinating journey of manifesting multiple dream boats, illustrating how the subconscious mind plays a pivotal role in turning desires into tangible outcomes. The episode delves into the neuroscience behind manifestation, highlighting how imagination and sensory experiences influence intentions in the subconscious. Dr. Resnick explains how the subconscious constantly scans your environment, aligning actions with your goals to create what might feel like serendipitous moments. This episode is for you if you're ready to understand how the subconscious mind shapes your reality and how to use that knowledge to manifest your dreams.   Tips in this episode: The subconscious mind is constantly active, processing and valuing experiences in ways that can manifest external realities, even outside conscious awareness. Providing clear and vivid intentions allows the subconscious mind to prioritize and manifest those desires over default or negative patterns. Understanding brain networks, such as the salience and default mode networks, can shed light on how manifestation works from a neurological perspective. Evaluating and altering limiting beliefs can transform personal and professional life experiences by fostering a growth mindset and improving health outcomes.     About The Guest: Dr. Steven Resnick is the Medical Director of the Mount Sinai Comprehensive Stroke Center. Board-certified in Neurology and Vascular Neurology, Dr. Resnick is an attending Neurologist with direct supervision of internal medicine and medical students at Mount Sinai Hospital. Dr. Resnick has co-authored a textbook entitled Practical Neuroimaging in Stroke and has published articles in the Journal of the Peripheral Nervous System, the Journal of Neurology, and the Journal of Neurology, Neurosurgery, and Psychiatry. He has lectured extensively on stroke prevention, acute ischemic stroke, practical Neuroimaging in cerebrovascular disease, and other related topics. Clinical research includes studies of drug therapies to treat Neuromuscular diseases.   Connect with Dr. Resnick Website: https://drstevenresnick.com/ Instagram: https://www.instagram.com/dr.stevenresnick Facebook: https://www.facebook.com/DrStevenResnick/ Podcast: https://drstevenresnick.com/the-healthy-mind-podcast/       Subscribe To The Manifested Podcast With Kathleen Cameron: Apple Podcast | YouTube | Spotify Connect With The Kathleen Cameron: Facebook | Instagram | LinkedIn | Youtube | TikTok | Kathleencameronofficial.com   Unlock Your Dreams with House of ManifestationA community where you take control of your destiny, manifest your desires, and create a life filled with abundance and purpose? Look no further than the House of Manifestation, where your transformation begins: https://houseofmanifestation.com/ About Kathleen Cameron: Kathleen Cameron, Chief Wealth Creator, 8-figure entrepreneur, and record-breaking author. In just 2 years, she built a 10 Million dollar business and continues to share her knowledge and expertise with all of whom she connects with.  With her determination, unwavering faith, and powers of manifestation, she has helped over 100,000 people attract more love, money, and success into their lives. Her innovative approaches to Manifestation and utilizing the Laws of Attraction have led to the creation of one of the top global success networks, Diamond Academy Coaching, thousands of students have been able to experience quantum growth. The force behind her magnetic field has catapulted many students into a life beyond their wildest dreams and she is just getting started. Kathleen helps others step into their true potential and become the best version of themselves with their goals met. Kathleen graduated with two undergraduate degrees from the University of Windsor and the University of Toronto with a master's degree in nursing leadership. Her book, “Becoming The One", published by Hasmark Publishing, launched in August 2021 became an International Best Seller in five countries on the first day.    This Podcast Is Produced, Engineered & Edited By: Simplified Impact

Gretchen Bandoli, Ph.D., highlights four major research initiatives within her division focused on maternal and child health. The Center for Better Beginnings studies medication and vaccine safety during pregnancy and lactation through ongoing cohort studies. The Mommy's Milk Human Milk Research Biorepository collects breast milk samples to investigate postnatal exposures. The SOMI study links medical records and geolocated data for over 7 million California births to examine maternal-child health outcomes. Bandoli also leads a site for the Healthy Brain and Child Development Study, a national project following 7,500 mother-child pairs over the first ten years of life with neurodevelopmental assessments and biological sampling. All projects welcome collaboration and emphasize long-term outcomes. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40772]

Gretchen Bandoli, Ph.D., highlights four major research initiatives within her division focused on maternal and child health. The Center for Better Beginnings studies medication and vaccine safety during pregnancy and lactation through ongoing cohort studies. The Mommy's Milk Human Milk Research Biorepository collects breast milk samples to investigate postnatal exposures. The SOMI study links medical records and geolocated data for over 7 million California births to examine maternal-child health outcomes. Bandoli also leads a site for the Healthy Brain and Child Development Study, a national project following 7,500 mother-child pairs over the first ten years of life with neurodevelopmental assessments and biological sampling. All projects welcome collaboration and emphasize long-term outcomes. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40772]

Gretchen Bandoli, Ph.D., highlights four major research initiatives within her division focused on maternal and child health. The Center for Better Beginnings studies medication and vaccine safety during pregnancy and lactation through ongoing cohort studies. The Mommy's Milk Human Milk Research Biorepository collects breast milk samples to investigate postnatal exposures. The SOMI study links medical records and geolocated data for over 7 million California births to examine maternal-child health outcomes. Bandoli also leads a site for the Healthy Brain and Child Development Study, a national project following 7,500 mother-child pairs over the first ten years of life with neurodevelopmental assessments and biological sampling. All projects welcome collaboration and emphasize long-term outcomes. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40772]

Gretchen Bandoli, Ph.D., highlights four major research initiatives within her division focused on maternal and child health. The Center for Better Beginnings studies medication and vaccine safety during pregnancy and lactation through ongoing cohort studies. The Mommy's Milk Human Milk Research Biorepository collects breast milk samples to investigate postnatal exposures. The SOMI study links medical records and geolocated data for over 7 million California births to examine maternal-child health outcomes. Bandoli also leads a site for the Healthy Brain and Child Development Study, a national project following 7,500 mother-child pairs over the first ten years of life with neurodevelopmental assessments and biological sampling. All projects welcome collaboration and emphasize long-term outcomes. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40772]

Gretchen Bandoli, Ph.D., highlights four major research initiatives within her division focused on maternal and child health. The Center for Better Beginnings studies medication and vaccine safety during pregnancy and lactation through ongoing cohort studies. The Mommy's Milk Human Milk Research Biorepository collects breast milk samples to investigate postnatal exposures. The SOMI study links medical records and geolocated data for over 7 million California births to examine maternal-child health outcomes. Bandoli also leads a site for the Healthy Brain and Child Development Study, a national project following 7,500 mother-child pairs over the first ten years of life with neurodevelopmental assessments and biological sampling. All projects welcome collaboration and emphasize long-term outcomes. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40772]

BUFFALO, NY — July 8, 2025 — As populations worldwide continue to age, understanding the mechanisms and manifestations of cognitive aging is increasingly urgent for science, medicine, and society. Age-related cognitive decline ranges from mild memory lapses to the onset of dementia, and is shaped by a complex interplay of molecular, cellular, systemic, and social determinants. In this special collection, Aging (Aging-US) seeks to bring together cutting-edge research that spans the cellular and molecular underpinnings of cognitive aging with insights into the psychosocial, behavioral, and environmental factors that modulate its course. By integrating basic biology with translational and societal dimensions, this collection aims to foster a holistic understanding of how and why cognitive function changes with age—and what can be done to preserve it. We welcome original research articles, reviews, and perspectives across model systems and human studies, particularly those that promote interdisciplinary insights and translational potential. POTENTIAL TOPICS Molecular and Cellular Mechanisms -Senescence, inflammation, and neurodegeneration in cognitive decline -Mitochondrial dysfunction and oxidative stress in aging neurons -Neurovascular aging and blood-brain barrier integrity -Single-cell and spatial transcriptomics of the aging brain -mTOR, autophagy, and proteostasis in age-related cognitive impairment -The role of glial cells (microglia, astrocytes) in brain aging Genetics and Biomarkers -Genetic risk factors and epigenetic modifications associated with cognitive aging -Biomarkers of cognitive resilience and vulnerability -Neuroimaging and fluid-based biomarkers in aging populations Interventions and Lifestyle Factors -Cognitive benefits of caloric restriction, exercise, or senolytic therapies -Preclinical and clinical trials targeting aging pathways to prevent cognitive decline -Impact of sleep, nutrition, and metabolic health on cognition in older adults -Use of cognitive strategies and compensatory techniques to maintain or enhance function in aging Environmental and Social Contexts -Impact of social isolation, education, and socioeconomic status on cognitive trajectories -Lifelong cognitive reserve and its determinants -Cross-cultural and demographic studies on aging and cognition -Digital health tools for monitoring or enhancing cognitive function in the elderly SUBMISSION DETAILS: -Submission Deadline: March 31, 2026 -Manuscript Format: Please follow the journal's submission guidelines -Peer Review: All submissions will undergo a rigorous peer-review process -Submission Link: https://aging.msubmit.net/cgi-bin/main.plex To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

For too long, Alcohol Use Disorder (AUD) has been misunderstood as a failure of willpower—but science tells a different story. In this episode, we dive into the neurological basis of addiction, exploring how AUD rewires the brain and why overcoming it requires more than sheer determination. We'll debunk myths, highlight the role of medical and psychological support, and offer insight into what real recovery looks like. If you've ever wondered why quitting alcohol feels impossible for some, this episode is for you.Find out about the free resources and all our books available at winspress.com.******************************************************************************************References for today's episode:Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction: A neurocircuitry analysis. The Lancet Psychiatry, 3(8), 760-773. https://doi.org/10.1016/S2215-0366(16)00104-Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. New England Journal of Medicine, 374(4), 363-371. https://doi.org/10.1056/NEJMra151148Goldstein, R. Z., & Volkow, N. D. (2011). Dysfunction of the prefrontal cortex in addiction: Neuroimaging findings and clinical implications. Nature Reviews Neuroscience, 12(11), 652-669. https://doi.org/10.1038/nrn311Bechara, A. (2005). Decision making, impulse control and loss of willpower to resist drugs: A neurocognitive perspective. Nature Neuroscience, 8(11), 1458-1463. https://doi.org/10.1038/nn158McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA, 284(13), 1689-1695. https://doi.org/10.1001/jama.284.13.168.Marlatt, G. A., & Donovan, D. M. (2005). Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. Guilford Press.

How do you turn massive clinical imaging data into insights that change lives? What does it take to move from a psychology undergrad to a pioneering role in pediatric brain research? And how can coding, connectomics, and curiosity shape a meaningful clinical career in neuroscience? In this inspiring episode of Neurocareers: Doing the Impossible!, we sit down with Dr. Puck Reeders, Senior Neuroscience Research Scientist at the Brain Institute at Nicklaus Children's Hospital. From her early days in Curacao to building novel neuroimaging pipelines in one of the nation's oldest pediatric epilepsy programs, Dr. Reeders shares her unique career path—and how she helps decode complex brain networks to improve surgical outcomes for children with intractable epilepsy. We explore: How connectomics and diffusion imaging guide surgical planning Her innovative research on white matter networks and neuromodulation responses The steep but rewarding path from zero coding skills to advanced tractography Tips for transitioning from psychology to clinical neuroscience Career advice for anyone eager to enter research-focused medical settings Whether you're a student exploring future careers, a neuroscientist curious about clinical impact, or just fascinated by how science meets medicine—you'll walk away informed and inspired. Chapters: 00:00:00 - Insights from a Neuroscience Research Scientist 00:03:00 - Functional Mapping Techniques for Epilepsy 00:08:43 - Transitioning from Medical School to Psychology 00:13:10 - Research Gaps in Epilepsy 00:17:10 - Understanding Connectomics in Epilepsy Treatment 00:21:53 - Combining Imaging Techniques in Research 00:24:50 - Coding Challenges in Research 00:27:12 - Coding Journey in Neuroscience 00:28:51 - Learning to Code: A Personal Journey 00:32:39 - The Importance of Networking 00:34:30 - Art's Role in Science Communication 00:37:38 - Landing a Job Through Networking 00:41:22 - Research Opportunities in Connectomics 00:46:49 - Exploring Diverse Career Opportunities 00:51:38 - Job Search Tips and Strategies 00:54:39 - Tips for Job Applications and Interviews 00:59:46 - From Medicine to Neuroscience Research 01:02:06 - Clinical Research and Pediatric Epilepsy About the Podcast Guest: Dr. Puck Reeders is a Senior Neuroscience Research Scientist at the Brain Institute at Nicklaus Children's Hospital in Miami, Florida https://www.nicklauschildrens.org/home Her work focuses on investigating aberrant brain networks in children with intractable epilepsy, applying advanced neuroimaging techniques to improve clinical outcomes in pediatric neurology. Originally from the Netherlands and raised on the island of Curaçao, Dr. Reeders brings a global perspective to her research. She holds a Bachelor of Science in Psychology and Chemistry from the University of Miami, and a PhD in Cognitive Neuroscience from Florida International University, where she also completed her postdoctoral training in the Allen Neurocircuitry and Cognition Lab. Dr. Reeders has over nine years of experience working with functional MRI (fMRI) and diffusion-weighted imaging (DWI) in both adults and children. Her current research explores the structural connectomics of pediatric epilepsy, the development of clinical imaging pipelines to detect white matter abnormalities, cortical dysplasias, and automated SPECT subtractions—bringing together cutting-edge science with translational clinical impact. Her expertise spans: Neuroimaging and clinical pipeline development Data analysis and scientific coding Translational neuroscience and surgical planning support Research project design and academic mentoring Outside of the lab, Dr. Reeders shares insights into neuroscience careers and research life on her educational Instagram: @Drpucky You can also connect with her professionally on LinkedIn:  https://www.linkedin.com/in/puckreeders/  About the Podcast Host: The Neurocareers podcast is brought to you by The Institute of Neuroapproaches (https://www.neuroapproaches.org/) and its founder, Milena Korostenskaja, Ph.D. (Dr. K), a career coach for people in neuroscience and neurotechnologies. As a professional coach with a background in neurotech and Brain-Computer Interfaces, Dr. K understands the unique challenges and opportunities job applicants face in this field and can provide personalized coaching and support to help you succeed. Here's what you'll get with one-on-one coaching sessions from Dr. K: Identification and pursuit of career goals Guidance on job search strategies, resume, and cover letter development Neurotech / neuroscience job interview preparation and practice Networking strategies to connect with professionals in the field of neuroscience and neurotechnologies Ongoing support and guidance to help you stay on track and achieve your goals You can always schedule a free neurocareer consultation/coaching session with Dr. K at https://neuroapproaches.as.me/free-neurocareer-consultation Subscribe to our Nerocareers Newsletter to stay on top of all our cool neurocareers news at updates https://www.neuroapproaches.org/neurocareers-news

It's time to rewire for wellness—your brain holds the blueprint for healing, and Dr. Steven Resnick is here to show you how! In this powerful episode of The Manifested Podcast, Kathleen Cameron sits down with neurologist Dr. Steven Resnick to explore how subconscious beliefs and identity shape our physical health. Discover how neurology and manifestation intersect—and how rewiring your mind could be the key to lasting wellness. Don't miss Dr. Resnick's holistic take on healing that goes far beyond traditional medicine.   In this episode: Your brain loves habits — even the unhealthy ones. Change takes awareness. Shifting your mindset can lead to real health breakthroughs. Positive self-talk and mindfulness help rewire old patterns. Beliefs and words can impact healing — even in medicine. Dr. Resnick shares how being present boosts well-being.   About The Guest: Dr. Steven Resnick is the Medical Director of the Mount Sinai Comprehensive Stroke Center. Board-certified in Neurology and Vascular Neurology, Dr. Resnick is an attending Neurologist with direct supervision of internal medicine and medical students at Mount Sinai Hospital. Dr. Resnick has co-authored a textbook entitled Practical Neuroimaging in Stroke and has published articles in the Journal of the Peripheral Nervous System, the Journal of Neurology, and the Journal of Neurology, Neurosurgery, and Psychiatry. He has lectured extensively on stroke prevention, acute ischemic stroke, practical Neuroimaging in cerebrovascular disease, and other related topics. Clinical research includes studies of drug therapies to treat Neuromuscular diseases.   Connect with Dr. Resnick Website: https://drstevenresnick.com/ Instagram: https://www.instagram.com/dr.stevenresnick Facebook: https://www.facebook.com/DrStevenResnick/ Podcast: https://drstevenresnick.com/the-healthy-mind-podcast/   Shop Iylia Premium Non-Alcoholics: https://iylia.com/   Subscribe To The Manifested Podcast With Kathleen Cameron: Apple Podcast | YouTube | Spotify Connect With The Kathleen Cameron: Facebook | Instagram | LinkedIn | Youtube | TikTok | Kathleencameronofficial.com   Unlock Your Dreams with House of ManifestationA community where you take control of your destiny, manifest your desires, and create a life filled with abundance and purpose? Look no further than the House of Manifestation, where your transformation begins: https://houseofmanifestation.com/ About Kathleen Cameron: Kathleen Cameron, Chief Wealth Creator, 8-figure entrepreneur, and record-breaking author. In just 2 years, she built a 10 Million dollar business and continues to share her knowledge and expertise with all of whom she connects with.  With her determination, unwavering faith, and powers of manifestation, she has helped over 100,000 people attract more love, money, and success into their lives. Her innovative approaches to Manifestation and utilizing the Laws of Attraction have led to the creation of one of the top global success networks, Diamond Academy Coaching, thousands of students have been able to experience quantum growth. The force behind her magnetic field has catapulted many students into a life beyond their wildest dreams and she is just getting started. Kathleen helps others step into their true potential and become the best version of themselves with their goals met. Kathleen graduated with two undergraduate degrees from the University of Windsor and the University of Toronto with a master's degree in nursing leadership. Her book, “Becoming The One", published by Hasmark Publishing, launched in August 2021 became an International Best Seller in five countries on the first day.    This Podcast Is Produced, Engineered & Edited By: Simplified Impact

In this episode, we explore the intersection of AI, machine learning, and healthcare through the lens of neuroimaging and epilepsy diagnosis. Dr. Gavin Winston shares insights from his work using MRI data and machine learning to uncover subtle abnormalities in brain function. We discuss the cultural and ethical barriers to AI adoption in medicine, how predictive data analysis could transform the diagnostic workflow, and what the future holds for medical imaging in a world increasingly shaped by intelligent systems.Featuring:Gavin Winston – LinkedIn, WebsiteChris Benson – Website, GitHub, LinkedIn, XDaniel Whitenack – Website, GitHub, XLinks:Detection of Epileptogenic Focal Cortical Dysplasia Using Graph Neural Networks: A MELD StudyMachine Learning in Neuroimaging across DisciplinesAutomated and Interpretable Detection of Hippocampal Sclerosis in Temporal Lobe Epilepsy: AID-HSLiterature review and protocol for a prospective multicentre cohort study on multimodal prediction of seizure recurrence after unprovoked first seizureDeep learning in neuroimaging of epilepsyNon-parametric combination of multimodal MRI for lesion detection in focal epilepsyDetection of covert lesions in focal epilepsy using computational analysis of multimodal magnetic resonance imaging data

In this episode, Jonathan Sackier is joined by Adrian Owen, Professor of Cognitive Neuroscience and Imaging at the University of Western Ontario. They explore Owen's groundbreaking research on consciousness in vegetative states, the ethical questions raised by his work, and the cutting-edge technology that has changed our understanding of the brain.  Timestamps:  00:00 – Introduction  02:46 – Taking one album on a desert island  04:03 – A groundbreaking discovery about vegetative states  06:58 – Owen's bestseller: ‘Into the Gray Zone'   11:18 – Where is the border between life and death?  15:40 – Cutting-edge technologies for brain imaging   20:11 – Applications of fMRI and EEG  24:41 – Does brain-training work?  31:09 – Implications for life support and end-of-life care  36:00 – Owen's three wishes for healthcare   

Can your hair type really prevent you from participating in neuroimaging research? In this episode, Beverley Isibor sits down with Dwaynica Greaves, a PhD candidate at UCL, to unpack the scope of a research study funded by the Centre for Equality Research in Brain Sciences. Along with the research team, Antonia Hamilton and Isla Jones, Dwaynica discusses how hair types and styles can impact participation. Additionally, they explore why accessibility in research matters, the biases in scientific equipment, and what can be done to make neuroimaging research more inclusive. Transcription link: https://www.ucl.ac.uk/brain-sciences/about-faculty/equality-diversity-and-inclusion/edi-chronicles-brain-sciences-podcast/edi-4 Date of episode recording: 2024-12-09T00:00:00Z Duration: 32:13 Language of episode: English Presenter:Beverley Isibor Guests: Dwaynica Greaves Producer: Teresa Baker

April 1 marks the beginning of Autism Awareness Month in the U.S. and the U.K. so I invited neuroscientist Dr. Gina Rippon on the pod to talk about what autism is, the history of its diagnosis, and how women and girls have been overlooked in autism research.About our guest: Professor Gina Rippon is Professor Emeritus of Cognitive NeuroImaging at Aston University in the UK. Her research involves the use of state-of-the-art brain imaging techniques to investigate developmental disorders such as autism, profiling different patterns of brain activity in autistic children and adults. Her current research explores the under-recognition of autism in women and girls, especially in neuroscience research. Her new book on this topic: The Lost Girls of Autism (UK)/Off the Spectrum (US) is released in April 2025.

In this episode of Talk Nerdy, Cara is joined by cognitive neuroscientist and neuroimaging expert, Gina Rippon. They discuss her forthcoming book (April 1 2025), “Off the Spectrum: Why the Science of Autism Has Failed Women and Girls”, which is a call to recognize the full spectrum of the autistic experience. Follow Gina: @ginarippon1

About our guest:Ilyse Genser is a pediatric neurologist and the associate program director of the pediatric neurology combined residency program at Children's National Hospital. She is originally from Westchester, New York, where she attended medical school at New York Medical College. She then completed her general pediatrics training at Brown University in Providence, Rhode Island, and came to Washington, D.C., to complete her child neurology training at Children's National Hospital. Learning Objective:Develop an expert-guided approach to choosing appropriate neuroimaging techniques for critically ill children.References: Shulman, J. G., & Abdalkader, M. (2023). Imaging of Central Nervous System Ischemia. http://journals.lww.com/continuumHakimi, R. (2023). Imaging of Central Nervous System Hemorrhage. http://journals.lww.com/continuumJordan, J. T., & Gerstner, E. R. (2023). Imaging of Brain Tumors. http://journals.lww.com/continuumBarnette, A. R., Horbar, J. D., Soll, R. F., Pfister, R. H., Nelson, K. B., Kenny, M. J., Raju, T. N. K., Bingham, P. M., & Inder, T. E. (2014). Neuroimaging in the Evaluation of Neonatal Encephalopathy. PEDIATRICS, 133(6), e1508–e1517. https://doi.org/10.1542/peds.2013-4247Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

About our guest:Ilyse Genser is a pediatric neurologist and the associate program director of the pediatric neurology combined residency program at Children's National Hospital. She is originally from Westchester, New York, where she attended medical school at New York Medical College. She then completed her general pediatrics training at Brown University in Providence, Rhode Island, and came to Washington, D.C., to complete her child neurology training at Children's National Hospital. Learning Objective:Develop an expert-guided approach to choosing appropriate neuroimaging techniques for critically ill children.References: Shulman, J. G., & Abdalkader, M. (2023). Imaging of Central Nervous System Ischemia. http://journals.lww.com/continuumHakimi, R. (2023). Imaging of Central Nervous System Hemorrhage. http://journals.lww.com/continuumJordan, J. T., & Gerstner, E. R. (2023). Imaging of Brain Tumors. http://journals.lww.com/continuumBarnette, A. R., Horbar, J. D., Soll, R. F., Pfister, R. H., Nelson, K. B., Kenny, M. J., Raju, T. N. K., Bingham, P. M., & Inder, T. E. (2014). Neuroimaging in the Evaluation of Neonatal Encephalopathy. PEDIATRICS, 133(6), e1508–e1517. https://doi.org/10.1542/peds.2013-4247Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

Neuroimaging is a tool to classify and ascertain the etiology of epilepsy in people with first or recurrent unprovoked seizures. In addition, imaging may help predict the response to treatment. To maximize diagnostic power, it is essential to order the correct imaging sequences. In this episode, Aaron Berkowitz, MD, PhD, FAAN speaks with Christopher T. Skidmore, MD, author of the article “Neuroimaging in Epilepsy,” in the Continuum February 2025 Epilepsy issue. Dr. Berkowitz is a Continuum® Audio interviewer and professor of clinical neurology at the University of California, San Francisco Dr. Skidmore is  an associate professor of neurology and vice-chair for clinical affairs at Thomas Jefferson University, Department of Neurology in Philadelphia, Pennsylvania. Additional Resources Read the article: Neuroimaging in Epilepsy Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz Guest: @ctskidmore  Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Berkowitz: This is Dr Aaron Berkowitz, and today I'm interviewing Dr Christopher Skidmore about his article on neuroimaging in epilepsy, which appears in the February 2025 Continuum issue on epilepsy. Welcome to the podcast, Dr Skidmore. Would you please introduce yourself to our audience?  Dr Skidmore: Thank you for having me today. I'm happy to talk to you, Dr Berkowitz. My name is Christopher Skidmore. I'm an associate professor of neurology at Thomas Jefferson University in Philadelphia. I'm a member of the Jefferson Comprehensive Epilepsy Center and also serve as the vice chair of clinical affairs for the department.  Dr Berkowitz: Thank you very much for joining us and for this fantastic article. It's very comprehensive, detailed, a very helpful review of the various types of brain pathology that can lead to epilepsy with very helpful images and descriptions of some of the more common findings like mesial temporal sclerosis and some of the less common ones such as cortical malformations, heterotopia, ganglioglioma, DNET. So, I encourage all of our listeners to read your article and take a close look at those images. So, hopefully you can recognize some of these findings on patients' neuroimaging studies, or if you're studying for the right or the boards, you can recognize some of these less common congenital malformations that can present in childhood or adulthood with epilepsy. In our interview today, what I'd like to do is focus on some practical tips to approaching, ordering, and reviewing different neuroimaging studies in patients with epilepsy. So to start, what's your approach when you're reviewing an MRI for a patient with a first seizure or epilepsy? What sequence do you begin with and why, how do you proceed through the different sequences and planes? What exactly are you looking for?  Dr Skidmore: It's an important question. And I think to even take a step back, I think it's really important, when we're ordering the MRI, we really need to be specific and make sure that we're mentioning the words seizures and epilepsy because many radiology centers and many medical centers have different imaging protocols for seizure and epilepsy patients as compared to, like, a stroke patient or a brain tumor patient. I think first off, we really need to make sure that's in the order, so that way the radiologist can properly protocol it. Once I get an image, though, I treat an MRI just like I would a CAT scan approach with any patient, which is to always approach it in the same fashion. So, top down, if I'm looking at an axial image. If I'm looking at a coronal image, I might start at the front of the head and go to the back of the head. And I think taking that very organized approach and looking at the whole brain in total first and looking across the flare image, a T2-weighted image and a T1-weighted image in those different planes, I think it's important to look for as many lesions as you can find. And then using your clinical history. I mean, that's the value of being a neurologist, is that we have the clinical history, we have the neurological exam, we have the history of the seizure semiology that can might tell us, hey, this might be a temporal lobe seizure or hey, I'm thinking about a frontal lobe abnormality. And then that's the advantage that we often have over the radiologist that we can then take that history, that exam, and apply it to the imaging study that we're looking at and then really focus in on those areas. But I think it's important, and as I've illustrated in a few of the cases in the chapter, is that don't just focus on that one spot. You really still need to look at the whole brain to see if there's any other abnormalities as well. Dr Berkowitz: Great, that's a very helpful approach. Lots of pearls there for how to look at the imaging in different planes with different sequences, comparing different structures to each other. Correspondent reminder, listeners, to look at your paper. That's certainly a case where a picture is worth a thousand words, isn't it, where we can describe these. But looking at some of the examples in your paper, I think, will be very helpful as well. So, you mentioned mentioning to the neuroradiologist that we're looking for a cause of seizures or epilepsy and epilepsy protocols or MRI. What is sort of the nature of those protocols if there's not a quote unquote “ready-made” one at someone 's center in their practice or in their local MRI center? What types of things can be communicated to the radiologist as far as particular sequences or types of images that are helpful in this scenario? Dr Skidmore: I spent a fair amount of time in the article going over the specific MRI protocol that was designed by the International League Against Epilepsy. But what I look for in an epilepsy protocol is a high-resolution T2 coronal, a T2 flare weighted image that really traverses the entire temporal lobe from the temporal tip all the way back to the most posterior aspects of the temporal lobe, kind of extending into the occipital lobe a little bit. I also want to see a high resolution. In our center, it's usually a T1 coronal image that images the entire brain with a very, very thin slice, and usually around two millimeters with no gaps. As many of our neurology colleagues are aware, when you get a standard MRI of the brain for a stroke or a brain tumor, you're going to have a relatively thick slice, anywhere from five to eight millimeters, and you're actually typically going to have a gap that's about comparable, five to eight millimeters. That works well for large lesions, strokes, and big brain tumors, but for some of the tiny lesions that we're talking about that can cause intractable epilepsy, you can have a focal cortical dysplasia that's literally eight- under eight millimeters in size. And so, making sure you have that nice T1-weighted image, very thin slices with no gaps, I think is critical to make sure we don't miss these more subtle abnormalities. Dr Berkowitz: Some of the entities you describe in your paper may be subtle and more familiar to pediatric neurologists or specialized pediatric neuroradiologists. It may be more challenging for adult neurologists and adult neuradiologists to recognize, such as some of the various congenital brain malformations that you mentioned. What's your approach to looking for these? Which sequences do you focus on, which planes? How do you use the patient 's clinical history and EEG findings to guide your review of the imaging? Dr Skidmore: It's very important, and the reason we're always looking for a lesion---especially in patients that we're thinking about epilepsy surgery---is because we know if there is a lesion, it increases the likelihood that epilepsy surgery is going to be successful. The approach is basically, as I mentioned a little bit before, is take all the information you have available to you. Is the seizure semiology, is it a hyper motor semiology or hyperkinetic semiology suggestive of frontal lobe epilepsy? Or is it a classic abdominal rising aura with automatisms, whether they be manual or oral automatisms, suggesting mesial temporal lobe epilepsy? And so, take that clinical history that you have to help start to hone your eye into those individual locations. But then, once you're kind of looking in these nonlesional cases, you're also then looking at the EEG and where their temporal lobe spikes, where their frontal lobe spikes, you know, using that and pulling that information in. If they saw a neuropsychologist pulling in the information in from the neuropsychological evaluation; if they have severe reductions in verbal memory, you know, focusing on the dominant temporal lobe. So, in a right-handed individual, typically the left temporal lobe. And kind of then really spending a lot of time going slice at a time, very slowly, because in some of these vocal-cortical dysplasias it can be just the blurring of the gray-white margin. What I find easiest is to identify that gray-white margin and almost track it. Like, you use the mouse to kind of track it around and say, can I outline the exact border of the gray white margin in the frontal lobe that I'm interested in or the temporal lobe that I'm interested in, kind of looking for those subtle abnormalities. Often as neurologists, we don't have the luxury of being able to immediately reformat. As I mentioned, our T1 volume acquisition study is done in the coronal plane, but sometimes you might want it in the axial plane. And so, I might reach out to the radiologist and say, hey, can you reformat this in the axial plane because I'm interested in the frontal lobe epilepsy and it's a little bit better at looking at it in that plane? And I'll have them reformat and put it back on the pack so I can look at it in that manner. And so that's a, kind of another strategy is to take what you have, but also then go back to the radiologist and say, I need to look at it this a different way. Can you reformat it for me? Looking for that gray-white matter junction is the nice way to pick up for kind of subtle cortical dysplasias. And then when you see an abnormality, to be able to put the T1, the T2, and the flare image all up next to each other and use the technology built into most of our browsers to put on what's called the localizer mode, where I can highlight a specific spot that I'm seeing on the T1 and then very easily quickly see, what does it look like on the T2? What does it look like on the flare? To kind of quickly decide, is it a true abnormality or am I only seeing it on one slice because of an artifact on that one imaging sequence? And I think that's the biggest kind of key is to make sure, is it an artifact or is it not an artifact? That's kind of the most common thing that we, I think, get confused with.  Dr Berkowitz: So, some very helpful pearls there in terms of reviewing the imaging, being in dialogue with our neuroradiology colleagues to think about potentially reacquiring certain images on certain planes or looking at the images with our neuroradiology colleagues to let them know more about the clinical history and where we're sort of zooming in about possible abnormalities.  Dr Skidmore: I would just add in there that when looking at especially the mesial temporal structures, because of a lot of artifacts that can be present in an individual MRI machine, it's not uncommon that the mesial temporal structure will appear brighter because of an MRI magnet artifact. And so, it's a good key to look at the hippocampus compared to the insula. And so, the hippocampus and the insula should have similar signal characteristics. You're seeing the hippocampus is bright, but the insula  ipsilateral to it's normal intensity. That would suggest that that's probably a true hyperintensity on the flare-weighted image as opposed to if both are bright, unless you're suspecting a hemispheric abnormality, it's more likely to be a kind of artifact in the MRI machine. Dr Berkowitz: Okay. Those are really helpful tips, not just to analyze the hippocampus and medial temporal lobe itself---let's remember our anatomy and the circuit of Papez---and to look at associated structures for supporting evidence of a possible abnormality in the hippocampus itself. It looks like there may be something subtle. We can use some additional information from the image to try to decide if that is real or artifactual, and of course correlating with the clinical picture and EEG. I'd like to talk briefly now about some other imaging modalities that you discuss in your paper, the use of functional imaging such as PET, SPECT and fMRI. Let's talk a bit about each of these. When would you order a PET scan for a patient with epilepsy? What would you be looking for and how would you be using that to make clinical decisions?  Dr Skidmore: Yeah, so these functional imaging modalities are really utilized when we're evaluating somebody that's not responding to medications. So, they're medically intractable, and we're wondering, could they be a candidate for epilepsy surgery? And so, most of these imaging modalities are really relegated to the world of epileptologists at surgical epilepsy centers. I wanted to include them, though, in the article because I do think it's important for general neurologists to understand kind of what they are, because invariably a patient sees me and then they go back to their general neurology and be like, hey, Doctor Skidmore said I had this PET scan abnormality. What do you think? So, I think it's a good idea for general neurologists to kind of understand them. So, probably the oldest that we've utilized is the FDG PET scan, basically looking at fluorodeoxyglucose and the brain's utilization of glucose. As we all remember, again, glucose is the primary molecule for energy and ATP production in the brain. And so basically, by injecting radioactive glucose in the interictal state--- so not during a seizure but in between seizures---areas of the brain that are not taking up the radiotracer will show as being hypometabolic. So, low metabolism. And hypometabolic regions in the interictal state have been associated with onset regions for epileptic seizures. Let's say you have a patient clinical history, you think they have temporal of epilepsy, EEG suggests temporal of epilepsy, but the MRI is nonlesional, meaning there's no abnormality that anybody could appreciate even at a 3 Tesla scanner. We'll get an FDG PET scan and see, is there hypo metabolism in that temporal lobe of interest? And if there is, well, that's been shown through several published papers, that's just as valuable as having an abnormality on the MRI. And so, we often again use these PET scans, especially in nonlesional cases, to try to find that subtle cortical dysplasia. Now you have your nice epilepsy protocol MRI, it says it's nonlesional. You get your PET scan, it shows hypometabolism in a region of the frontal lobe, let's say, in a in a frontal lobe epilepsy case. And then often we go back, we kind of talked about strategy of how you find those subtle lesions. Then you go back and say, well, look, this gyrus specifically on the PET scan said it's abnormal. You end up looking for really subtle, very tiny abnormalities that, even with somebody that's skilled, often at first review gets missed. So, that's how we use the PET scan. The SPECT scan is done typically in the ictal state. So, now somebody's in an epilepsy monitoring unit often, where you're injecting radio tracer at the exact moment that somebody starts having a seizure. And we know when there's increased seizure activity, the increased seizure activity---let's say it's from my right temporal lobe---is going to increase cerebral blood flow transiently to the right temporal lobe. And then if that seizure discharge spreads from the right temporal lobe maybe to the entire right hemisphere and eventually becomes a focal to bilateral tonic chronic seizure by spreading to the other side, the entire brain is going to be hypoperfused at that point. So, if you want to, as soon as the seizure starts, inject that radio tracer to see, where is the blood flow earliest in the seizure? And then we might do an interictal SPECT when you're not having a seizure. Look at, all right, what's the normal blood flow when somebody's not seizing? What's it like when they're having a seizure? And then the area that has increased activity would- might suggest that's where the seizure started from. But we have to be very careful because again, some seizures can spread very rapidly. So, if you delay injecting an injection ten, fifteen, twenty seconds, the seizure could have already propagated to another region of the brain, giving you a false positive in another location. So, you have to be very careful about that modality. I think what's most exciting is the functional MRI because the functional MRI, for many, many centers, is replacing a very old technique called the WADA test. So, in the WADA test, typically you place a catheter angiogram into the internal carotid artery and transiently introduce a sedative medication to put, let's say, the left hemisphere to sleep because you wanted to see what functions were still active in the right hemisphere. And then the surgeon would move the catheter or the right internal carotid artery, and you inject a sedative on that side after the left hemisphere is recovered and see what the left hemisphere can do. And we used that for language dominance, we used that for memory dominance. And while most individuals did fine with angiograms, unfortunately complications do occur and there's injury to the artery, there could be strokes that can- that have happened, which can be quite devastating for the patient. And so, functional MRI is a nice, noninvasive way for us to map out language function, motor function, sensory function, visual function, and is starting to show some usefulness also for mapping out kind of memory function, dominant memory function, meaning verbal memory compared to visual memory. To be able to do those things noninvasively becomes really important because, if we're talking about epilepsy surgery, we want to make you seizure-free but neurologically intact. And so, we need to understand the relationship between where we think the seizures are coming from and where eloquent cortex is so we can properly counsel you and avoid those regions during any planned surgery. Those are the three most common functional imaging modalities that we're using now to supplement the rest of the presurgical work.  Dr Berkowitz: Very helpful. So, these are studies, PET, SPECT, and fMRI, that would really be obtained predominantly in patients in whom epilepsy surgery was being considered to have more precise lesion localization, as well as with the fMRI to get a better sense of how to provide the safest maximal resection of epileptogenic tissue while preserving functions. Dr Skidmore: That's a perfect summary.  Dr Berkowitz: Fantastic. This has been a really helpful interview with Dr Skidmore and a really fantastic article. As I said, a picture is worth a thousand words, so I definitely encourage you to read the article and look at the images of some of the conditions we've been talking about and some of these findings that can be seen on interictal PET or ictal SPECT to get a sense of the visual aspects of what we've been discussing. So again, today I've been interviewing Dr Christopher Skidmore about his article on neuroimaging and epilepsy, which appears in the most recent issue of Continuum on Epilepsy. Be sure to check out Continuum audio episodes from this and other issues. And thank you so much to our listeners for joining us today.  Dr Skidmore: Thank you for having me. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Dr. Richard Haier is an emeritus professor of Pediatric Neurology at UC Irvine, who spent his career studying the neuroscience of intelligence. Over the course of his career, Haier has come to believe in the existence of a “g-factor,” a measurable quantity of broad spectrum intelligence that is universally predictive of success in all cultures. He also believes that intelligence is a fixed characteristic, and that it's possible to predict someone's intelligence by watching how their brain works when trying to solve a puzzle. We sit down with him to figure out how far one can take this theory of intelligence before running headlong into a heartless social darwinism, why intelligence research feels so creepy, if IQ tests are actually measuring what we think they're measuring, if intelligence is really the thing that we should be optimizing for, and if it's possible for technology to make us dumber. Don't miss the historic cosmology summit in Portugal this summer!!! DEMYSTICON 2025 ANNUAL MEETING June 12-16: https://demystifysci.com/demysticon-2025 PATREON: get episodes early + join our weekly Patron Chat https://bit.ly/3lcAasB MERCH: Rock some DemystifySci gear : https://demystifysci.myspreadshop.com/all AMAZON: Do your shopping through this link: https://amzn.to/3YyoT98 SUBSTACK: https://substack.com/@UCqV4_7i9h1_V7hY48eZZSLw@demystifysci 00:00 Go! 00:09:28 Flynn Effect and G Factor 00:15:40 Testing, Practice, and Intelligence 00:26:58 The Relationship Between Intelligence, Motivation, and Test Scores 00:31:09 Heritability and Societal Implications of Intelligence 00:35:51 The Social Value of Intelligence Versus Athletic Ability 00:41:54 IQ Levels and Educational Attainment 00:48:03 The Dilution of College Degrees 00:53:07 Educational System Critique 00:57:24 Intelligence and Occupational Success 01:01:40 Bureaucracy and Talent in Academia 01:06:13 Intelligence and Personal Success 01:19:20 Enhancing Intelligence through Drugs 01:25:28 Brain Efficiency and Intelligence 01:31:12 Tetris Study and Brain Efficiency 01:44:20 Predicting Intelligence through Brain Imaging 01:49:58 Brain Structure and Cognitive Prediction 01:52:00 Challenges in Enhancing Intelligence 02:04:22 Environmental and Genetic Interplay 02:14:02 Understanding Autism and Intelligence 02:19:56 Artificial Intelligence vs. Human Intelligence 02:28:21 Technology's Impact on Skill Development 02:32:55 Flynn Effect and Educational Implications 02:39:24 Technology and Its Impact on Children 02:45:08 Societal Roles and Intelligence Levels 02:48:09 Meaning and Societal Functionality #IQTests, #Neuroscience, #intelligence, #iqtest, #ArtificialIntelligence, #HumanIntelligence, #CognitiveScience, #BrainFunction, #iq , #Neuroimaging, #AIvsHumans, #TechImpact, #philosophypodcast, #sciencepodcast, #longformpodcast Check our short-films channel, @DemystifySci: https://www.youtube.com/c/DemystifyingScience AND our material science investigations of atomics, @MaterialAtomics https://www.youtube.com/@MaterialAtomics Join our mailing list https://bit.ly/3v3kz2S PODCAST INFO: Anastasia completed her PhD studying bioelectricity at Columbia University. When not talking to brilliant people or making movies, she spends her time painting, reading, and guiding backcountry excursions. Shilo also did his PhD at Columbia studying the elastic properties of molecular water. When he's not in the film studio, he's exploring sound in music. They are both freelance professors at various universities. - Blog: http://DemystifySci.com/blog - RSS: https://anchor.fm/s/2be66934/podcast/rss - Donate: https://bit.ly/3wkPqaD - Swag: https://bit.ly/2PXdC2y SOCIAL: - Discord: https://discord.gg/MJzKT8CQub - Facebook: https://www.facebook.com/groups/DemystifySci - Instagram: https://www.instagram.com/DemystifySci/ - Twitter: https://twitter.com/DemystifySci MUSIC: -Shilo Delay: https://g.co/kgs/oty671

Iain McGilchrist is a Consultant Emeritus of the Bethlem and Maudsley Hospital, London, a former research Fellow in Neuroimaging at Johns Hopkins University Medical School, Baltimore, a former Fellow of All Souls College, Oxford, an Associate Fellow of Green Templeton College, Oxford, a Fellow of the Royal College of Psychiatrists, a Fellow of the Royal Society of Arts, and a former Fellow of the Institute of Advanced Studies in Stellenbosch. He has published original research on neuroimaging in schizophrenia, the phenomenology of schizophrenia, and other topics. Some of his many books include "The Master and his Emissary: The Divided Brain and the Making of the Western World" (2009), The Divided Brain and the Search for Meaning; Why Are We So Unhappy? (2012), and "The Matter with Things: Our Brains, Our Delusions and the Unmaking of the World" (2021). Full Episode: https://www.youtube.com/watch?v=2UEXDs4mouU Title: "Iain McGilchrist: Why Are Our Brains Divided? Hemispheric Differences And Its Impact On The Mind" CONNECT: - Website: https://tevinnaidu.com - Podcast: https://creators.spotify.com/pod/show/mindbodysolution - YouTube: https://youtube.com/mindbodysolution - Twitter: https://twitter.com/drtevinnaidu - Facebook: https://facebook.com/drtevinnaidu - Instagram: https://instagram.com/drtevinnaidu - LinkedIn: https://linkedin.com/in/drtevinnaidu ============================= Disclaimer: The information provided on this channel is for educational purposes only. The content is shared in the spirit of open discourse and does not constitute, nor does it substitute, professional or medical advice. We do not accept any liability for any loss or damage incurred from you acting or not acting as a result of listening/watching any of our contents. You acknowledge that you use the information provided at your own risk. Listeners/viewers are advised to conduct their own research and consult with their own experts in the respective fields.

This week, we are joined by Anila D'Mello, an assistant professor at UT Southwestern, whose groundbreaking research uses neuroimaging to explore the brain circuits that support language and cognition in autism. Dr. D'Mello will share insights from her work on cerebro-cerebellar circuits and how they differ in neurodevelopmental disorders. Join us as we discuss how these findings can transform our understanding of autism and inform future interventions. Download episode to learn more! Resources  A seat at the (language) table: incorporating the cerebellum into frameworks for language processingLeBel, A., D'Mello, A.M Current Opinion in Behavioral Sciences 2024   Exclusion of females in autism research: Empirical evidence for a "leaky" recruitment-to-research pipeline.D'Mello AM, Frosch IR, Li CE, Cardinaux AL, Gabrieli JDE, Autism Res 2022 Aug   Cerebellar Contributions to Social Cognition in ASD: A Predictive Processing Framework.Frosch IR, Mittal VA, D'Mello AM, Front Integr Neurosci 2022 16 810425   Enhanced rationality in autism spectrum disorder.Rozenkrantz L, D'Mello AM, Gabrieli JDE, Trends Cogn Sci 2021 08 25 8 685-696   Differential Behavioral and Neural Effects of Regional Cerebellar tDCS.Rice LC, D'Mello AM, Stoodley CJ, Neuroscience 2021 05 462 288-302   Anxiety, Motivation, and Competence in Mathematics and Reading for Children With and Without Learning Difficulties.Pollack C, Wilmot D, Centanni TM, Halverson K, Frosch I, D'Mello AM, Romeo RR, Imhof A, Capella J, Wade K, Al Dahhan NZ, Gabrieli JDE, Christodoulou JA, Front Psychol 2021 12 704821 ............................................................... Autism weekly is now found on all of the major listening apps including apple podcasts, google podcasts, stitcher, Spotify, amazon music, and more. Subscribe to be notified when we post a new podcast. Autism weekly is produced by ABS Kids. ABS Kids is proud to provide diagnostic assessments and ABA therapy to children with developmental delays like Autism Spectrum Disorder. You can learn more about ABS Kids and the Autism Weekly podcast by visiting abskids.com.

In this interview with Dr. Bret Scher, Dr. Corinde Wiers, Assistant Professor of Psychiatry at the University of Pennsylvania, unveils her groundbreaking research on using ketogenic therapy to treat alcohol use disorder (AUD). Dr. Wiers dives into how ketones, as an alternative energy source, may alleviate withdrawal symptoms, reduce cravings, and transform the landscape of addiction recovery. This conversation covers: The science of brain energy metabolism and how ketones are preferred over glucose in AUD. Results from clinical trials, including reductions in withdrawal severity and the need for benzodiazepines. Neuroimaging data that shows how ketogenic diets affect the brain's reward system and craving mechanisms. The broader implications of metabolic therapies for treating mood disorders, addiction, and brain health. Dr. Wiers shares her journey from studying alcohol use disorders in Europe to leading cutting-edge research in the U.S. She provides insights into the challenges and opportunities of integrating metabolic therapies into mainstream mental health and addiction treatment. Experts Featured Dr. Corinde Wiers X: @CorindeW LinkedIn: https://www.linkedin.com/in/corinde-wiers-479a9219/ https://www.med.upenn.edu/csa/corindewiers.html Resources: Ketogenic diet reduces alcohol withdrawal symptoms in humans and alcohol intake in rodents https://pubmed.ncbi.nlm.nih.gov/33837086/ Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at https://metabolicmind.org/ About us: Metabolic Mind is a non-profit initiative of Baszucki Group working to transform the study and treatment of mental disorders by exploring the connection between metabolism and brain health. We leverage the science of metabolic psychiatry and personal stories to offer education, community, and hope to people struggling with mental health challenges and those who care for them. Our channel is for informational purposes only. We are not providing individual or group medical or healthcare advice nor establishing a provider-patient relationship. Many of the interventions we discuss can have dramatic or potentially dangerous effects if done without proper supervision. Consult your healthcare provider before changing your lifestyle or medications. #MetabolicMind #MetabolicNeuroscience #KetogenicMetabolicTherapy #NutritionalKetosis #AlternativeTreatment #PsychiatricMedication#KetogenicTherapy #KetoforAlcoholUseDisorder #AlcoholUseDisorder

Send us a textAbout the guest: Joshua Siegel, MD, PhD is a psychiatrist & systems neuroscience at New York University. He uses functional imaging to study the effects of psychedelics and other drugs on the human brain.Episode summary: Nick and Dr. Siegel discuss: fMRI and how it works; relationship between neural activity and blood flow; functional connectivity & the default mode network of the human brain; the functional effects of psilocybin on the brain; the role that subjective & expectancy effects in psychedelics medicine; and more.Related episodes:M&M #173: Psychedelics, Consciousness, Psychiatry, Psychology, Mental Health & the Entropic Brain HypothesisM&M #163: Anesthesia, Placebo Effects, Consciousness, Subjectivity, MDMA, Ketamine, Opioids, Psychedelics*This content is never meant to serve as medical adviceSupport the showAll episodes (audio & video), show notes, transcripts, and more at the M&M Substack Affiliates: MASA Chips—delicious tortilla chips made from organic corn and grass-fed beef tallow. No seed oils, artificial ingredients, etc. Use code MIND for 20% off. SiPhox Health—Affordable, at-home bloodwork w/ a comprehensive set of key health marker. Use code TRIKOMES for a 10% discount. Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off. Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase. Consensus: AI-powered academic research tool. Find & understand the best science, faster. Free 1-year premium sub with code MINDMATTERSPECIAL Learn all the ways you can support my efforts

Explore the science and potential of hypnosis as Dr. David Spiegel, Stanford's leading expert in mind-body medicine, joins Dave Asprey to reveal how hypnosis can radically enhance cognition, mental clarity, and resilience. In this episode of The Human Upgrade, you'll learn how hypnosis influences the brain's most vital networks, including the default mode network and executive control, to break mental barriers and amplify focus, perception, and healing. Discover how hypnosis, unlike traditional meditation or neurofeedback, accelerates response times, manages pain, and even helps alleviate PTSD. Dr. Spiegel shares stories of patients overcoming chronic pain and trauma through self-hypnosis, and details the mechanisms that make hypnosis a powerful tool for emotional and physical transformation. Dive into the fascinating brain science behind the practice, from theta brainwave induction to deep sensory modulation, and learn simple self-hypnosis techniques that can elevate mental performance, improve sleep quality, and instill lasting calm. If you're seeking a powerful, accessible way to biohack your brain and harness the potential of your mind, this episode delivers the insights and tools you need to make hypnosis your ultimate cognitive upgrade. Sponsors Quantum Upgrade | Go to Quantum Upgrade | Go to https://quantumupgrade.io/Dave for a free trial. Zbiotics | Go to https://zbiotics.com/DAVE for 15% off your first order. Resources: • Dr. David Spiegel's Website – https://med.stanford.edu/profiles/david-spiegel • Reveri Hypnosis App – https://reveri.com (available on App Store and Google Play) • Dave Asprey's Website – https://daveasprey.com • Danger Coffee – https://dangercoffee.com • Danger Coffee Instagram – https://www.instagram.com/dangercoffeeofficial/ • Dave Asprey's Linktree – https://linktr.ee/daveasprey • Dave Asprey's Book: Smarter Not Harder – https://daveasprey.com/books • Upgrade Collective: Join The Human Upgrade Podcast Live – https://www.ourupgradecollective.com • Own an Upgrade Labs – https://ownanupgradelabs.com • Upgrade Labs – https://upgradelabs.com • 40 Years of Zen – Neurofeedback training for advanced cognitive enhancement https://40yearsofzen.com Timestamps • 00:00 – Introduction to Hypnosis • 00:59 – Dave Asprey Introduces Dr. David Spiegel • 02:03 – Dr. Spiegel's Journey into Hypnotherapy • 06:06 – The Power of Hypnosis in Medical Practice • 11:19 – Understanding Hypnosis and Brain Function • 16:14 – Hypnosis for PTSD and Trauma • 19:33 – Hypnosis vs. EMDR: Key Differences • 22:30 – Pain Management through Hypnosis • 31:06 – The Impact of Psychedelics on Cancer Patients • 33:04 – Exploring Psychedelic-Assisted Neurofeedback • 34:05 – Neuroimaging and Brain Activity in Hypnosis • 35:22 – Hypnosis and Cognitive Enhancement • 38:53 – Hypnosis for Sleep and Stress Management • 42:26 – Hypnosis and the “Manchurian Candidate” Concept • 48:21 – Hypnosis and the Immune System • 53:11 – Live Hypnosis Session with Dave Asprey • 58:46 – Conclusion and Final Thoughts See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Imagine unlocking a superpower hidden within your mind. Imagine feeling in control of how you engage with the world, how you heal and grow, and how you manage stress. If you're a TBMer, you already know how powerful hypnosis can be, but today we're giving you a fascinating conversation with Dr. David Spiegel, a leading expert in the field of hypnosis and neuroscience. Dive into the incredible world of the mind, where the brain's power to alter perception unfolds before your eyes. Dr. Spiegel shares captivating insights from his groundbreaking research, revealing how hypnosis can create cognitive flexibility, enhance focus, and even facilitate rapid healing. Discover the awe-inspiring potential of your mind to transform your life through practical, science-backed techniques. From personal anecdotes to revolutionary studies, this episode promises to ignite your curiosity and inspire you to harness the full power of your mind. Join us for an extraordinary journey into the wonders of hypnosis and its impact on the mind-body connection. **Trigger Warning: discussion about traumatic event (00:22:10 through 00:22:58)** Find the Complete Show Notes Here -> https://tobemagnetic.com/expanded-podcast In This Episode We Talk About:The role of hypnosis in altering perception and managing painDr. Spiegel's background and family history in psychiatryNeuroimaging studies on the effects of hypnosis on the brainThe significance of the default mode network in hypnosisDissociation and its impact on focus and attentionCognitive flexibility and its benefits in hypnosisHypnosis for managing chronic pain and reducing opioid dependencyFunctional connectivity in the brain during hypnosisThe role of the anterior cingulate cortex in hypnosisHypnosis for stress management and enhancing sleep qualityHypnotic induction techniques and their applicationsThe connection between hypnosis and neuroplasticityPractical applications of hypnosis in daily lifeThe Reveri app and its functionalitiesDr. Spiegel's personal experiences with hypnosis  THEMES / TIME STAMPS:Neuroimaging and brain activity during hypnosis (00:13:30)**Trigger Warning: discussion about traumatic event (00:22:10 through 00:22:58)**How hypnosis can be used to manage chronic pain, reduce anxiety, improve sleep, and support personal growth, with real-life examples and clinical trial results. (00:38:45)Unpacking perceived helplessness, and cognitive flexibility (00:55:40)Resources: TBM SUMMER SALE ☀️LIVE NOW Get the lowest prices of the season and up to $96 off 2024 TBM Summer Challenge - Get Out of Your Own WayLIVE NOW - Join anytime Share your challenge manifestations stories for a chance to be featured on The Expanded Podcast Bon Charge - 15% off with code MAGNETICRed Light Face MaskRed Light Neck and Chest Mask BITE - 20% off your first order with code MAGNETICFresh mint toothpaste bits  Learn about effectivity of hypnosis on pain management hereLearn about effectivity of hypnosis on quitting smoking hereLearn about our Challenge more in this episodeFind the Safety DI and all workshops mentioned inside our Pathway Membership! (Including all of our Unblocked DIs) Connect with Dr. SpiegelConnect with Dr. Spiegel + Reveri on IGGo to https://www.reveri.com/ to sign up for the app, and be sure to use the exclusive code EXPANDED for 20% off. Where To Find Us!@tobemagnetic (IG)@Lacyannephillips@Jessicaashleygill@tobemagnetic (youtube)@expandedpodcast Other ResourcesSubmit to Be a Process GuestText Us: +1-213-423-5226 - (texting is only for US, Canada, & Puerto Rico)Alexis Smart x TBM EXPANDED Flower RemedyDid you Finish the Manifestation Challenge? Share your experience with us! Free Offerings to Get You StartedLearn the Process! Expanded Podcast - How to Manifest Anything You Desire Get Expanded! The Motivation - Testimonial LibraryNeed Help Identifying Your Block? Access our FREE Find Your Biggest Block Exercise

What is consciousness? Neil deGrasse Tyson and Chuck Nice learn about the study of consciousness and how psychedelics could uncover the inner mechanisms of the brain with anesthesiologist and founder of the Michigan Psychedelic Center, George Mashour. NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free here: https://startalkmedia.com/show/exploring-consciousness-with-george-mashour/Thanks to our Patrons Andrew O., Johnathan Kuhl, Nathan champlin, Matthew Smith-Burlage, Kareem Austin, Charles Blaksmith, and İtKopuk Cansel Işıksel for supporting us this week.